The β1 adrenoceptor (AR) blocker metoprolol normalises βAR cascade and caveolar protein expression and restores β1AR responsiveness in failing right ventricular myocytes.

Ruth Norman, Rachel Stones, Amelia S Power, Ed White, Sarah C Calaghan, Ewan D Fowler

Abstract read

In one paragraph

Article in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruth NormanSchool of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, UK.

Rachel StonesSchool of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, UK.

Amelia S PowerDepartment of Physiology, University of Auckland, Auckland, New Zealand.

Ed WhiteSchool of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, UK.

Sarah C CalaghanSchool of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, UK.

Ewan D FowlerSchool of Biosciences, College of Biological and Life Sciences, University of Cardiff, Cardiff, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Right ventricular (RV) failure is the leading cause of death in pulmonary artery hypertension (PAH) and treatments that preserve RV contractility are urgently required. β-adrenoceptor blockers (BB) are used clinically in left ventricular failure to improve β-adrenoceptor (AR) responsiveness but it is not known whether they confer the same benefits in RV failure. Here we tested this using the rat monocrotaline (MCT) model of PAH. When PAH was established, treatment commenced with β1AR-selective metoprolol (10 mg/kg/day; MCT + BB group) or vehicle (MCT group). In isolated RV myocytes from MCT, inotropic and lusitropic responses to β1AR stimulation were blunted vs. non-failing controls (CON), and this was recovered by BB treatment. Comparable effects on amplitude/kinetics of the Ca

Indexed as

beta-adrenoceptorbeta-blockerCaveolaeHeart failureMonocrotalinePulmonary arterial hypertensionRight ventricle

Identifiers

PMID42495427

DOI10.1016/j.jmccpl.2026.100857

PMCPMC13393817

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.